• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1994年急性移植物抗宿主病分级共识会议。

1994 Consensus Conference on Acute GVHD Grading.

作者信息

Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, Thomas E D

机构信息

University of Texas MD Anderson Cancer Center, Houston 77030, USA.

出版信息

Bone Marrow Transplant. 1995 Jun;15(6):825-8.

PMID:7581076
Abstract

Grading acute graft-versus-host disease (GVHD) is usually based on quantification of rash, serum bilirubin and diarrhea. Standard criteria have been developed and used for > 20 years by most transplant centers. However, neither the standard GVHD grading system nor any of several revisions has been validated in the context of GVHD prophylaxis with cyclosporine. The 1994 Consensus Conference on Acute GVHD Grading held in Keystone in January 1994 provided an opportunity to: (1) review data regarding these standard criteria; (2) determine if there are sufficient data to revise these criteria; and (3) develop recommendations for reporting results of GVHD prevention trials. Data were provided for 8249 patients from 12 large transplant centers and 2 transplant registries. Standard GVHD grading criteria were found to distinguish different mortality risks and treatment response rates. Analysis of new data suggested that persistent nausea with histologic evidence of GVHD but no diarrhea be included as stage 1 gastrointestinal GVHD. Additional studies were recommended to evaluate heterogeneity of outcome within GVHD grades prior to making further revisions. To improve comparability between publications, reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GVHD corrected for graft failure and potential interventions for early relapse. Additional information should include indications for therapy of GVHD and response.

摘要

急性移植物抗宿主病(GVHD)的分级通常基于皮疹、血清胆红素和腹泻的量化评估。多数移植中心已经制定并使用标准标准20多年了。然而,无论是标准的GVHD分级系统还是其多个修订版本,均未在环孢素预防GVHD的背景下得到验证。1994年1月在基斯通召开的急性GVHD分级共识会议提供了一个机会:(1)回顾有关这些标准标准的数据;(2)确定是否有足够的数据来修订这些标准;(3)制定关于报告GVHD预防试验结果的建议。来自12个大型移植中心和2个移植登记处的8249例患者的数据被提供。发现标准的GVHD分级标准能够区分不同的死亡风险和治疗反应率。对新数据的分析表明,伴有GVHD组织学证据但无腹泻的持续性恶心应列为1级胃肠道GVHD。建议在进行进一步修订之前开展更多研究,以评估GVHD分级内结局的异质性。为提高不同出版物之间的可比性,GVHD预防试验报告应准确描述所使用的分级系统,并应报告经移植失败校正的II-IV级和III-IV级GVHD的精算发生率以及早期复发的潜在干预措施。其他信息应包括GVHD治疗的指征和反应。

相似文献

1
1994 Consensus Conference on Acute GVHD Grading.1994年急性移植物抗宿主病分级共识会议。
Bone Marrow Transplant. 1995 Jun;15(6):825-8.
2
Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.异基因骨髓移植后急性移植物抗宿主病的药物预防
Clin Pharm. 1993 Oct;12(10):736-61.
3
Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.环孢素和甲泼尼龙用于预防和治疗移植物抗宿主病的剂量对异基因骨髓移植后生存和复发的影响。
Bone Marrow Transplant. 1999 Jan;23(2):145-50. doi: 10.1038/sj.bmt.1701529.
4
Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.通过去除骨髓移植物中的CD4+淋巴细胞并减少CD8+淋巴细胞来预防高危患者的移植物抗宿主病。
Bone Marrow Transplant. 1999 Mar;23(5):443-50. doi: 10.1038/sj.bmt.1701493.
5
Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry.HLA 全相合同胞干细胞移植后经典的 Glucksberg 标准与 IBMTR 严重程度指数在急性移植物抗宿主病分级中的比较。国际骨髓移植登记处。
Bone Marrow Transplant. 1999 Aug;24(3):283-7. doi: 10.1038/sj.bmt.1701899.
6
Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study.慢性移植物抗宿主病的胃肠道受累:一项临床病理研究。
Biol Blood Marrow Transplant. 2003 Jan;9(1):46-51. doi: 10.1053/bbmt.2003.49999.
7
Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.采用环孢素A联合甲氨蝶呤作为预防措施,可维持急性白血病异基因骨髓移植受者的移植物抗白血病效应。欧洲血液与骨髓移植组急性白血病工作组。
Bone Marrow Transplant. 1996 Nov;18(5):921-9.
8
Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.骨髓移植者关于慢性移植物抗宿主病诊断、分级及治疗的共识。国际骨髓移植登记处委员会
Bone Marrow Transplant. 1989 May;4(3):247-54.
9
[Analysis of acute liver "graft-versus-host disease" following allogeneic myeloablative stem cell transplant].[异基因清髓性干细胞移植后急性肝脏“移植物抗宿主病”的分析]
Rinsho Ketsueki. 2004 Jan;45(1):57-60.
10
A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.一种使用抗CD6单克隆抗体偶联磁珠的新型骨髓T细胞清除方法及其在异基因骨髓移植中预防急性移植物抗宿主病的临床应用:一项I-II期试验结果
Int J Hematol. 1999 Jan;69(1):27-35.

引用本文的文献

1
Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.地西他滨联合减低强度预处理方案用于接受异基因造血干细胞移植的复合完全缓解的老年急性髓系白血病患者:一项多中心、单臂、2期试验。
Lancet Reg Health West Pac. 2025 Aug 12;61:101664. doi: 10.1016/j.lanwpc.2025.101664. eCollection 2025 Aug.
2
Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.含索拉非尼和供体淋巴细胞输注的挽救性治疗与异基因造血干细胞移植后复发的FLT3野生型急性髓系白血病患者预后改善相关。
Biomark Res. 2025 Aug 20;13(1):106. doi: 10.1186/s40364-025-00816-9.
3
The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysis.他克莫司血药浓度对单倍体造血干细胞移植中急性移植物抗宿主病及移植结局的影响:一项回顾性分析
Cell Transplant. 2025 Jan-Dec;34:9636897251366368. doi: 10.1177/09636897251366368. Epub 2025 Aug 14.
4
Significance of kidney and spleen volumes analyzed via three-dimensional computed tomography prior to allogeneic stem cell transplantation.异基因干细胞移植前通过三维计算机断层扫描分析肾脏和脾脏体积的意义。
Sci Rep. 2025 Jul 31;15(1):27982. doi: 10.1038/s41598-025-12373-0.
5
Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study.重组人血小板生成素在儿童异基因造血干细胞移植中的安全性和有效性:一项队列研究。
World J Stem Cells. 2025 Jul 26;17(7):106579. doi: 10.4252/wjsc.v17.i7.106579.
6
A molecular-based risk score for predicting leukemia-free survival in adult AML patients undergoing Allo-HSCT.一种基于分子的风险评分,用于预测接受异基因造血干细胞移植的成年急性髓系白血病患者的无白血病生存期。
iScience. 2025 Jul 7;28(8):113077. doi: 10.1016/j.isci.2025.113077. eCollection 2025 Aug 15.
7
COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study.异基因造血干细胞移植受者对COVID-19疫苗的反应:一项真实世界前瞻性队列研究的见解
Vaccines (Basel). 2025 Jul 3;13(7):726. doi: 10.3390/vaccines13070726.
8
IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.国际预后评分系统-骨髓(IPSS-M)在预后分层方面优于国际预后评分系统-修订版(IPSS-R),并为接受异基因造血干细胞移植的极高危骨髓增生异常综合征患者指导有效的干预措施。
Discov Oncol. 2025 Jul 11;16(1):1315. doi: 10.1007/s12672-025-03155-1.
9
Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study.罗米司亭与重组人血小板生成素在脐带血移植中的比较:一项单中心回顾性研究。
Ann Hematol. 2025 Jul 9. doi: 10.1007/s00277-025-06490-z.
10
Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia.不同干细胞来源的异基因造血干细胞移植治疗婴幼儿急性髓系白血病的临床结局
Sci Rep. 2025 Jul 8;15(1):24452. doi: 10.1038/s41598-025-05602-z.